A Phase 1/2 clinical trial tested autologous CD133+ bone marrow–derived stem cells for Asherman syndrome and reported preliminary signals of endometrial repair, investigators said. The single-arm study evaluated safety, feasibility, and early efficacy endpoints, including restoration of endometrial thickness and improvement in menstrual function. Researchers highlighted the autologous approach as a strategy to avoid immunogenicity while promoting tissue regeneration. Investigators called the results encouraging but preliminary, noting the need for larger, controlled trials to verify durability, fertility outcomes, and mechanistic endpoints. Reproductive specialists and biotech developers focused on regenerative gynecology will monitor follow-up data and potential commercialization paths for cell-based uterine repair therapies.